AU2010235993A1 - Hangover cure - Google Patents
Hangover cure Download PDFInfo
- Publication number
- AU2010235993A1 AU2010235993A1 AU2010235993A AU2010235993A AU2010235993A1 AU 2010235993 A1 AU2010235993 A1 AU 2010235993A1 AU 2010235993 A AU2010235993 A AU 2010235993A AU 2010235993 A AU2010235993 A AU 2010235993A AU 2010235993 A1 AU2010235993 A1 AU 2010235993A1
- Authority
- AU
- Australia
- Prior art keywords
- hangover
- phase
- glutathione
- nac
- factors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Abstract Dr Hangover is a beverage that alleviates hangover symptoms due to the everyday exposure to free radicals such as pesticides, carcinogens (cigarettes), alcohol, carbon fuel emissions, ultra violet light and radiation. Dr Hangover is specially formulated to provide the body with the essential co-factors that are important in the detoxification process for the body to digest and remove toxins via excretion.
Description
Editorial Note 2010235993 There are 3 pages of description WHY DO SOME PEOPLE GET SICK FROM TOXICITY AND SOME DON'T? There are two factors which influence the toxic exposure of your body, and its impact on your health. The first is the amount and type of toxin that you are exposed to; the second is the resources your body has to deal with it, or how well you "detoxify". That is why two people with similar toxic exposure can respond very differently, with one having no noticeable effects and the other developing chronic illness. The first person has a better capacity to detoxify. One of the unfortunate facts about our modern life is that our environments are inherently toxic and becoming more so every day. LIVER DETOX: Phase 1 - Breaks down toxins & chemicals into intermediate metabolites (IM's). The IM's can be more easily cleared via Phase 2 detox. Phase 1 detox is initiate via the Cytochrome P450 enzyme pathway in the liver. Toxins are usually broken down by oxidation, reduction or hydrolysis. This can either transform the toxin into a water soluble form, which allows excretion by the kidneys or converts it to a more chemically active form to be metabolised further by Phase 2 in the liver. Phase 1 detox results in the production of free radicals as toxins are transformed. Without sufficient antioxidant protection, these free radicals can damage the liver and other body tissues. Phase 2 - Involves the conjugation of IM's with a variety of different enzymes. The conjugation reaction either neutralizes the IM's or makes the metabolite easier to eliminate via either bile or urinary excretion. Co-factors required for Phase 1 detox: - Vitamins B1, B2, B3, B6, Folate, B12, C - Glutathione, Cysteine, Glutamine, Glycine - BCAA's - Copper, Magnesium, Zinc, Uniquness of Blend 1. NAC is needed for the production of glutathione and helps maintain glutathione levels in the cells. Supplementing with NAC can boost the levels of protective enzymes in the body, slowing the cellular damage that is characteristic of aging. It may also reduce the frequency and duration of infections. Combined with L Glutamine, NAC offers a powerful energy boost. Therefore by implementing L-Glutamine and Nacetyl cysteine (NAC) into the formula, the two substituents complement each other as they both aid to help form the powerful antioxidant glutathione and help form what is known as a synergism: (the interaction of elements that when combined produce a total effect that is greater than the sum of the individual elements, contributions, etc). 2. Riboflavin vitamin B2 an essential co-factor for proper phase 1 detoxification pathway works alongside NAC to help neutralize the toxins or free radicals and the B2 will complement the NAC to help move the toxins into phase 2 detoxification pathway in order to expedite the removal of the toxins and create less damage. 3. Riboflavin Vit B2, Nicotinamide Vit B3, and Pyridoxine HCL Vit B6 all complement each other as they act as co-factors for phase 1 detoxification. Alcohol will increase the work load or demand for these co-factors and without them, the digestion of alcohol will be inhibited until more is formed and therefore will allow the alcohol to stick around allowing for oxidation of the cells to occur ie(cell damage) 4. Ascorbic acid and NAC complement each other as ascorbic acid helps keep the glutathione that is produced from the NAC in its reduced form so that it can continue acting as an antioxidant. 5. The formula provides all of the needed essential co-factors for proper phase 1 detoxification of alcohol and toxins overall. The following formula combines phase 1 co-factors folic acid, Vitamins B2, B3, B6 and ascorbic acid. Together these ingredients form a unique blend allowing for effective support in moving toxins such as alcohol into proper phase 2 conjugation pathway. 6. Lipoic Acid synersises with ascorbic acid, NAC and glutathione as the lipoic acid aids to help recycle antioxidants therefore aiding to increase and allow constant replenishment of glutathione in the liver hepatocytes. Lipoic Acid is a thiol increases the reduced proportions of extracellular cysteine and glutathione in hepatoma cell cultures.Thus, addition of thiols increases the availability of cysteine which increases the production of glutathione. Alpha lipoic acid (ALA) is known as the all purpose antioxidant. It is powerful in its own right, and also as a recycler of vitamins C. It can restore the antioxidant properties of these vitamins after they have already neutralized free radicals 7. Silybum Marianum (Milk Thistle) is a powerful antioxidant and free radical scavenger on its own. Milk Thistle protects the hepatocytes (liver cells) and also induces a regeneration of cells therefore can speed up the formation of new liver cells and reverse the damage induced via free radicals such as alcohol and toxins to the liver cells. Milk Thistle and N-acetylcysteine together form a unique blend in that they compliment each other as N-acetlycysteine will aid in the removal of free radicals and Milk Thistle will provide protection to the liver cells. Future research may lead to an effective method for treating hepatitis C patients. 8. Overall this formula is extremely unique as N-Acetyl Cysteine, L-Glutamine, Ascorbic Acid, Lipoic Acid, Milk Thistle and Japanese Knotweed are all key antioxidants that will provide complete protection against the damaging effects on the body due to free radical exposure. 9. This formula is also unique in that it not only increases Glutathione levels via N Acetlycysteine and L-Glutamine, but also provides the body with the proper phase 1 and 2 co factors in order to provide the body with an effective detoxification pathway 10. Never before has a beverage been designed to perform not only an effective detoxification pathway to remove the toxins by providing the phase 1 co factors NAC, Vitamin B2,B3,B6, C and Folic Acid but providing the body with an effective phase 2 detoxification pathway co factors as well NAC and Glutathione. Key to note is that increasing the only recyclable antioxidant in the body Glutathione and the most powerful one maximum protection will be obtained.
Formula for Dr Hangover N-Acetyl Cysteine (NAC) 60mg L-Glutamine 15mg Riboflavin (Vit B2) 4mg Niacin / Nicotinamide (Vit B3) 20mg Pyridoxine HCL (Vit B6) 5mg Ascorbic C (Vit C) 20mg Folate (Folic acid) 10mcg Lipoic Acid 5mg Silybum Marianum (Milk Thistle) 10mg Resveratrol 2mg
Claims (6)
1. removes toxins quickly out of the body
2. alleviates hangover symptoms associated with alcohol consumption
3. decreases oxidation or damage to the cells
4. increases the antioxidant glutathione in the liver
5. Protects and coast the cells
6. Replenishes natural energy carriers in the citric acid cycle
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010235993A AU2010235993A1 (en) | 2010-10-25 | 2010-10-25 | Hangover cure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010235993A AU2010235993A1 (en) | 2010-10-25 | 2010-10-25 | Hangover cure |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2010235993A1 true AU2010235993A1 (en) | 2012-05-10 |
Family
ID=46637983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2010235993A Abandoned AU2010235993A1 (en) | 2010-10-25 | 2010-10-25 | Hangover cure |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2010235993A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1023090B1 (en) * | 2014-06-25 | 2016-11-21 | Pharomed | COMPOSITION |
EP3278793A1 (en) * | 2016-08-04 | 2018-02-07 | ppsph. GmbH | Composition for the treatment of veisalgia |
-
2010
- 2010-10-25 AU AU2010235993A patent/AU2010235993A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1023090B1 (en) * | 2014-06-25 | 2016-11-21 | Pharomed | COMPOSITION |
EP3278793A1 (en) * | 2016-08-04 | 2018-02-07 | ppsph. GmbH | Composition for the treatment of veisalgia |
WO2018024887A1 (en) * | 2016-08-04 | 2018-02-08 | Ppsph. Gmbh | Composition for the treatment of veisalgia |
CN109715168A (en) * | 2016-08-04 | 2019-05-03 | Ph股份公司 | For treating the composition being still drank after a night |
CN116059220A (en) * | 2016-08-04 | 2023-05-05 | Ph股份公司 | Composition for treating hangover |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Flora | Nutritional components modify metal absorption, toxic response and chelation therapy | |
Mouritz | Implications of the COVID-19 pandemic on China's Belt and Road Initiative | |
Fink et al. | Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial | |
IN2012DN01964A (en) | ||
WO2008112565A3 (en) | Method and composition for treating cancer | |
Garg et al. | Efficacy and tolerability of advanced glycation end-products inhibitor in osteoarthritis: a randomized, double-blind, placebo-controlled study | |
Abraham et al. | Protective effect of aminoguanidine against cyclophosphamide-induced oxidative stress and renal damage in rats | |
NO20065676L (en) | Prevention of arterial restenosis with active vitamin D compounds. | |
Mahaboob Basha et al. | Suppression of mitochondrial oxidative phosphorylation and TCA enzymes in discrete brain regions of mice exposed to high fluoride: amelioration by Panax ginseng (Ginseng) and Lagerstroemia speciosa (Banaba) extracts | |
WO2006044101A3 (en) | Method and composition for supplementation of nutritional deficiencies in renal patients | |
MX2011009137A (en) | Method of folding absorbent article. | |
AU2010235993A1 (en) | Hangover cure | |
CU20080054A7 (en) | COMPOSITIONS WITH IRON SUPPLEMENT WITH IMPROVED TOLERANCE | |
De et al. | Allylpyrocatechol attenuates methotrexate-induced hepatotoxicity in a collagen-induced model of arthritis | |
Ganash | Anticancer potential of ascorbic acid and inorganic selenium on human breast cancer cell line MCF-7 and colon carcinoma HCT-116 | |
Li et al. | Time-and dose-dependent allelopathic effects and mechanisms of kaempferol on toxigenic Microcystis growth | |
Pérez-Fuentes et al. | Enniatins A1 and B1 alter calcium homeostasis of neuronal cells leading to apoptotic death | |
WO2009054458A1 (en) | Composition for reducing the level of glucose, malondialdehyde-modified ldl, homocysteine and/or c-reactive protein in blood | |
WO2007021504A3 (en) | Methods for prophylactic and therapeutic nutritional supplementation | |
Khan et al. | Protective effect of alpha-lipoic acid on progression of cataract formation in fructose-induced experimental cataract | |
WO2003061597A3 (en) | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | |
WO2007013987A3 (en) | Supplement composition and method of use in enhancement of methylation process | |
Mehra et al. | In-vitro and in-vivo functional observation studies to establish therapeutic potential of alpha-ketoglutarate against methotrexate induced liver injury | |
TW200715997A (en) | Method for prevention of formation of abnormal odor in beverage composition | |
Lysne et al. | Riboflavin: a scoping review for Nordic Nutrition Recommendations 2023 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |